Paradigm Shifting to Early Treatment of Rheumatoid Arthritis

Min Chan Park; Soo-Kon Lee

doi:10.5124/jkma.2003.46.11.965

Journal List > J Korean Med Assoc > v.46(11) > 1080313

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Lee: Paradigm Shifting to Early Treatment of Rheumatoid Arthritis

Special Issue I

Arthritis

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2003; 46(11): 965-971.

Published online: 30 November 2003

DOI: https://doi.org/10.5124/jkma.2003.46.11.965

Paradigm Shifting to Early Treatment of Rheumatoid Arthritis

Min Chan Park, M.D., Soo-Kon Lee, M.D.

Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Korea. mcpark@yumc.yonsei.ac.kr, sookonlee@yumc.yonsei.ac.kr

(open-access):

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The past decade has greatly enhanced our understanding of rheumatoid arthritis (RA). Not only have new drug therapies become available, but this period has witnessed dramatic changes in treatment strategies as well. Since 1989, when the proposal on reversing the pyramid approach (the stepdown bridge concept) was published, the concept of early and aggressive treatment of RA has become the leading paradigm. The theory underlying this approach is based on a better understanding of the devastating long term consequences of RA in most patients, and the logical tenet that irreversible damage must be prevented before it occurs. Evidence has shown the irreversible joint damage in RA occurs early in the disease, making a "wait and see" approach unacceptable. Thus, it appears logical to begin treatment as soon as a diagnosis of RA is confirmed, to slow disease progression by treatment with disease modifying antirheumatic drugs. This review will address the evidence supporting the benefit and the principles of early treatment, as well as the current update on pharmacological management in early RA.

Keywords: Rheumatoid arthritis, Early treatment, Pharmacological management, Disease modifying antirheumatic drug

References

1. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis : a 19-year study of radiographic progression. Arthritis Rheum. 1998. 41:1571–1582.

2. Wilske KR, Healey LA. Remodeling the pyramid : a concept whose time has come. J Rheumatol. 1989. 16:565–567.

3. Kaarela K, Kauppi MJ, Lehtinen KE. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol. 1995. 24:279–281.

4. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995. 34:Suppl. 74–78.

5. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early : a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002. 46:357–365.

6. Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Symmons D, et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis : prospective cohort study. BMJ. 1996. 313:471–476.

7. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis : the HERA Study. Am J Med. 1995. 98:156–168.

8. Abu-Shakra M, Toker R, Flusser D, Flusser G, Friger MS, Buskila D, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Arthritis Rheum. 1998. 41:1190–1195.

9. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Schenk Y, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996. 124:699–707.

10. Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, Esdaile JM, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis : a 3 year follow up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol. 2000. 27:623–629.

11. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis:early presenters continue to do well. J Rheumatol. 1998. 25:1072–1077.

12. Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, Van't Hof MA, van Riel PL, et al. No increased mortality in patients with rheumatoid arthritis : up to 10 years of follow up from disease onset. Ann Rheum Dis. 2000. 59:954–958.

13. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease : a reappraisal. Arthritis Rheum. 2003. 48:12–20.

14. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis : clinical efficacy, disease-modifying properties, and side effects : a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002. 136:1–12.

15. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis : 2001 update. Arthritis Rheum. 2001. 44:1496–1503.

16. van de Putte LBA. Single agents in early rheumatoid arthritis : results of key randomized trials of single agents in early rheumatoid arthritis. J Rheumatol. 2002. 29:Suppl. 13–19.

17. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy / toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 1992. 35:1117–1112.

18. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van der Linden S, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997. 350:309–318.

19. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum. 1994. 37:1487–1491.

20. Lipsky PE, van der Heijde DM, Clair EW, Furst DE, Breedveld FC, Maini RN, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000. 343:1594–1602.

21. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Finck BK, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000. 343:1586–1593.

22. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Finck BK, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis : two-year radiographic and clinical outcomes. Arthritis Rheum. 2002. 46:1443–1450.

23. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Sun G, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis : A large, international, multi-center, placebo-controlled trial. Arthritis Rheum. 2003. 48:927–934.

24. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis:evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002. 46:2029–2033.

25. Verburg RJ, Toes RE, Fibbe WE, Breedveld FC, van Laar JM. High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis : a review. Hum Immunol. 2002. 63:627–637.

TOOLS

Similar articles